Prosecution Insights
Last updated: April 19, 2026

Examiner: NOBLE, MARCIA STEPHENS

Tech Center 1600 • Art Units: 1632

This examiner grants 67% of resolved cases

Performance Statistics

66.9%
Allow Rate
+6.9% vs TC avg
888
Total Applications
+40.3%
Interview Lift
1170
Avg Prosecution Days
Based on 837 resolved cases, 2023–2026

Rejection Statute Breakdown

6.1%
§101 Eligibility
20.1%
§102 Novelty
22.4%
§103 Obviousness
33.9%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17749788 RECOMBINASE COMPOSITIONS AND METHODS OF USE Non-Final OA FLAGSHIP PIONEERING INNOVATIONS VI, LLC
18163607 Peptide Conjugated Hydrogel Substrate for the Maintenance and Expansion of Human Pluripotent Stem Cells Final Rejection University of Pittsburgh - Of the Commonwealth System of Higher Education
18327976 MURINE-MHC-DEFICIENT HLA-TRANSGENIC NOD-MOUSE MODELS FOR T1D THERAPY DEVELOPMENT Non-Final OA The Jackson Laboratory
18336001 HUMAN PRIMARY MYELOFIBROSIS CELL STRAIN AND USE THEREOF Non-Final OA ZHEJIANG UNIVERSITY
17754597 MODULATION OF CELLULAR VIABILITY Non-Final OA Macquarie University
17567424 METHOD OF VACCINATION AGAINST CANCER USING PLASMA TREATED CANCER CELLS Non-Final OA Thomas Jefferson University
15578946 METHODS FOR IMPROVING FUNCTIONALITY IN NK CELL BY GENE INACTIVATION USING SPECIFIC ENDONUCLEASE Final Rejection Cellectis
17996074 CIRCULAR RNA COMPOSITIONS AND METHODS Final Rejection Orna Therapeutics, Inc.
18060183 ELIMINATION OF PROLIFERATING CELLS FROM STEM CELL-DERIVED GRAFTS Non-Final OA Research Development Foundation
18540096 NON-MEIOTIC ALLELE INTROGRESSION Final Rejection Recombinetics, Inc.
17995390 METHOD FOR PREPARING ANIMAL TISSUE-DERIVED BIOMATERIAL, ANIMAL TISSUE-DERIVED BIOMATERIAL PREPARED THEREBY, AND 3D PRINTING METHOD USING SAME Final Rejection T&R BIOFAB CO., LTD.
18512026 CELL REPROGRAMMING METHOD USING IMPOSITION OF PHYSICAL STIMULATION-MEDIATED ENVIRONMENTAL TRANSITION Non-Final OA STEMON INC.
18368240 METHOD OF MANUFACTURING AUTOLOGOUS CARDIAC LINEAGE CELLS Final Rejection ReGen Theranostics, Inc.
18121340 METHOD OF REPROGRAMMING CELLS Final Rejection ReGen Theranostics, Inc.
17661097 GENETIC MODIFICATION NON-HUMAN ORGANISM, EGG CELLS, FERTILIZED EGGS, AND METHOD FOR MODIFYING TARGET GENES Non-Final OA JAPAN SCIENCE AND TECHNOLOGY AGENCY
17596781 NUCLEIC ACID CONSTRUCT COMPRISING 5' UTR STEM-LOOP FOR IN VITRO AND IN VIVO GENE EXPRESSION Non-Final OA Glycom A/S
17771627 COMPOSITIONS AND METHODS FOR TREATING GLYCOGEN STORAGE DISORDERS Final Rejection Astellas Gene Therapies, Inc.
18249367 USING ORGANOIDS AND/OR SPHEROIDS TO CULTIVATE MEAT Non-Final OA Orbillion Bio, Inc.
17786483 METHOD OF MICROGLIA DIFFERENTIATION CAPABLE OF SECURING LARGE QUANTITY OF MICROGLIA BY USING 3D ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS Final Rejection CORESTEM CO.,LTD.
17978300 Prevention and treatment of bone and cartilage damage or disease Non-Final OA Xintela AB
17964399 MORTAL PLURIPOTENT STEM CELLS Non-Final OA ACCELERATED BIOSCIENCES CORP.
16301933 METHOD FOR FORMING A FUNCTIONAL NETWORK OF HUMAN NEURONAL AND GLIAL CELLS Final Rejection DEUTSCHES ZENTRUM FÜR NEURODEGENERATIVE ERKRANKUNGEN E.V.
17790797 METHODS AND COMPOSITIONS FOR PRODUCTION OF XENOGENEIC ISLET CELLS AND TREATMENT OF INSULIN-RESISTANT OR -DEFICIENT CONDITIONS WITH THE SAME Final Rejection Hangzhou Qihan Biotechnology Co., Ltd.
17747557 MEASLES VIRUS ENCODING A TUMOR ANTIGEN Final Rejection RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG
17731112 METHODS FOR ELECTRO-MECHANICAL TRANSFECTION Non-Final OA Kytopen Corporation
16641290 Non-Human Animal Model of Non-Alcoholic Fatty Liver Disease Non-Final OA The Nippon Dental University
17073580 STABILIZATION OF NON-DENATURED POLYPEPTIDES, NUCLEIC ACIDS, AND EXOSOMES IN A BLOOD SAMPLE AT AMBIENT TEMPERATURES Final Rejection Biomatrica, Inc.
14958358 CELL FUSION PROMOTER AND UTILIZATION OF THE SAME Non-Final OA Akio Hirata

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month